Recent Finacing
Recent Raise
Prolong Pharmaceuticals develops biopharmaceutical products for anemia caused by oxygen deficiency, advancing SANGUINATE™, an oxygen-transfer agent in clinical development, while expanding manufacturing capacity and infrastructure for additional indications.
Focus Areas
Total Raised
Funding round